Research progress of the surrogate of protection of pneumococcal conjugate vaccine
10.3760/cma.j.issn.0253-9624.2019.08.010
- VernacularTitle: 肺炎球菌结合疫苗免疫学替代终点的研究进展
- Author:
Yuanyuan WANG
1
;
Jingxin LI
2
;
Jiaqian CAO
1
;
Fengcai ZHU
2
Author Information
1. School of Public Health, Nanjing Medical University, Nanjing 211166, China
2. Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
- Publication Type:Review
- Keywords:
Pneumococcal infections;
Vaccine;
Surrogate of protection
- From:
Chinese Journal of Preventive Medicine
2019;53(8):851-854
- CountryChina
- Language:Chinese
-
Abstract:
There are many limitations in evaluating vaccine efficacy by comparing the incidence of clinical endpoint events (such as morbidity, bacterial colonization) between the vaccine group and the control group. Therefore, the researchers put forward the concept of Surrogate of protection to predict vaccine protection with immunological indicators. In 2012, WHO put forward the immunological substitution endpoint of pneumococcal vaccine, using 0. 35 μg/ml as the protective antibody level of pneumococcal vaccine. But subsequent studies have found that using this threshold to assess all vaccine serotypes may not be accurate.
